Inflammation and coagulation in urticaria and angioedema

Current Vascular Pharmacology

Volumn 10, Issue 5, 2012, Pages 653-658

  Cugno, Massimo ^a   Asero, Riccardo ^b   Tedeschi, Alberto ^c   Lazzari, Riccardo ^c   Marzano, Angelo V ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b CLINICA SAN CARLO   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Angioedema; C1 inhibitor deficiency; Histamine; Thrombin; Tissue factor; Urticaria

Indexed keywords

ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; COMPLEMENT COMPONENT C1S INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HISTAMINE; LOW MOLECULAR WEIGHT HEPARIN; OMALIZUMAB; PLACEBO; THROMBIN; TRANEXAMIC ACID; WARFARIN;

ANGIONEUROTIC EDEMA; ARTICLE; AUTOIMMUNE DISEASE; BLOOD CLOTTING; CHRONIC URTICARIA; DERMIS; DISEASE EXACERBATION; FIBRINOLYSIS; HUMAN; HYPERSENSITIVITY; INFLAMMATION; PATHOPHYSIOLOGY; REMISSION; THROMBOSIS; URTICARIA;

ANGIOEDEMA; ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; AUTOIMMUNE DISEASES; BLOOD COAGULATION; FIBRINOLYSIS; HISTAMINE; HUMANS; INFLAMMATION; REMISSION INDUCTION; THROMBIN; URTICARIA;

EID: 84864550881     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016112801784558     Document Type: Article

References (97)

1. Grattan CE, Sabroe RA, Greaves MW. Chronic urticaria. J Am Acad Dermatol 2002; 46: 645-57.
2. Greaves MW, Tan KT. Chronic urticaria: recent advances. Clin Rev Allergy Immunol 2007; 33: 134-43.
3. Cugno M, Nussberger J, Cicardi M, Agostoni A. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol 2003; 3: 311-7.
4. Zuberbier T, Asero R, Bindslev-Jensen C, et al.; Dermatology Section of the European Academy of Allergology and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64: 1427-43.
5. Gaig P, Olona M, Munoz Lejarazu D, et al. Epidemiology of urticaria in Spain. J Investig Allergol Clin Immunol 2004; 14: 214-20.
6. O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136: 197-201.
7. Frigas E, Park MA. Acute urticaria and angioedema: diagnostic and treatment considerations. Am J Clin Dermatol 2009; 10: 239-50.
8. Kaplan A. Urticaria and angioedema. In: Adkinson NFYJ, Busse WW, Bochner BS, et al., Eds. Middleton's allergy principles and practice. 6th ed. Philadelphia (PA): Mosby, 2003: 1537-58.
9. Shoemaker R. A search for the affective determinants of chronic urticaria. Psychosomatics 1963; 4:125-32.
10. Rees L. An etiological study of chronic urticaria and angioneurotic oedema. J Psychosom Res 1957; 2: 172.
11. Michaelsson G, Juhlin L. Urticaria induced by preservatives and dye additives in food and drugs. Br J Dermatol 1973; 88: 525-32.
12. Greaves MW. Chronic idiopathic urticaria and H pylori: not directly causative but could there be a link? ACI Int 2001; 13: 23-6.
13. Kaplan AP, Greaves M. Pathogenesis of chronic urticaria. Clin Exp Allergy 2009; 39: 777-87.
14. Church MK, Weller K, Stock P, Maurer M. Chronic spontaneous urticaria in children: itching for insight. Pediatr Allergy Immunol 2011; 22: 1-8.
15. Jirapongsananuruk O, Pongpreuksa S, Sangacharoenkit P, Visitsunthorn N, Vichyanond P. Identification of the etiologies of chronic urticaria in children: a prospective study of 94 patients. Pediatr Allergy Immunol 2010; 21: 508-14.
16. Brunetti L, Francavilla R, Miniello VL, et al. High prevalence of autoimmune urticaria in children with chronic urticaria. J Allergy Clin Immunol 2004; 114: 922-7.
17. Grattan CE, Wallington TB, Warin RP, Kennedy CT, Bradfield JW. A serological mediator in chronic idiopathic urticaria: a clinical, immunological and histological evaluation. Br J Dermatol 1986; 114: 583-90.
18. Gruber BL, Baeza ML, Marchese MJ, Agnello V, Kaplan AP. Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol 1988; 90: 213-7.
19. Hide M, Francis DM, Grattan CEH, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high affinity IgE receptor as a cause of histamine release in chronic urticaria. N Eng J Med 1993; 328: 1599-604.
20. Soundararajan S, Kikuchi Y, Joseph K, Kaplan AP. Functional assessment of pathogenic IgG subclasses in chronic autoimmune urticaria. J Allergy Clin Immunol 2005; 115: 815-21.
21. Ferrer M, Nakazawa K, Kaplan AP. Complement dependence of histamine release in chronic urticaria. J Allergy Clin Immunol 1999; 104: 169-72.
22. Kikuchi Y, Kaplan A. A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria. J Allergy Clin Immunol 2002; 109: 114-8.
23. Fiebiger E, Hammerschmid F, Stingl G, Maurer D. Anti-FcepsilonRIalpha autoantibodies in autoimmune-mediated disorders. Identification of a structure-function relationship. J Clin Invest 1998; 101: 243-51.
24. Puccetti A, Bason C, Simeoni S, et al. In chronic idiopathic urticaria autoantibodies against Fc epsilonRII/CD23 induce histamine release via eosinophil activation. Clin Exp Allergy 2005; 35: 1599-607.
25. Leznoff A, Sussman GL. Syndrome of idiopathic CU and angioedema with thyroid autoimmunity: a study of 90 patients. J Allergy Clin Immunol 1989; 84: 66-71.
26. Turktas I, Gokcora N, Demirsoy S, et al. The association of chronic urticaria and angioedema with autoimmune thyroiditis. Int J Dermatol 1997; 36: 187-90.
27. O'Donnell BF, Francis DM, Swana GT, Seed PT, Kobza Black A, Greaves MW. Thyroid autoimmunity in chronic urticaria. Br J Dermatol 2005; 153: 331-5.
28. Kikuchi Y, Fann T, Kaplan A. Antithyroid antibodies in chronic urticaria and angioedema. J Allergy Clin Immunol 2003; 112: 218.
29. Antiga E, Volpi W, Del Bianco E, Fabbri P, Caproni M. Plasma levels of metalloproteinase-9 are elevated in patients with chronic autoimmune urticaria. Br J Dermatol 2009; 161: 712-4.
30. Altrichter S, Boodstein N, Maurer M Matrix metalloproteinase-9: a novel biomarker for monitoring disease activity in patients with chronic urticaria patients? Allergy 2009; 64: 652-6.
31. Tedeschi A, Asero R, Lorini M, Marzano AV, Cugno M. Plasma levels of matrix metalloproteinase-9 in chronic urticaria patients correlate with disease severity and C-reactive protein but not with circulating histamine-releasing factors. Clin Exp Allergy 2010; 40: 875-81.
32. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-54.
33. Kanbe N, Tanaka A, Kanbe M, Itakura A, Kurosawa M, Matsuda H. Human mast cells produce matrix metalloproteinase 9. Eur J Immunol 1999; 29: 2645-9.
34. Ram M, Sherer Y, Shoenfeld Y. Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol 2006; 26: 299-307.
35. Marzano AV, Cugno M, Trevisan V, et al. Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophilmediated skin diseases. Clin Exp Immunol 2010; 162: 100-7.
36. Takahagi S, Mihara S, Iwamoto K, et al. Coagulation/fibrinolysis and inflammation markers are associated with disease activity in patients with chronic urticaria. Allergy 2010; 65: 649-56.
37. Altrichter S, Peter HJ, Pisarevskaja D, Metz M, Martus P, Maurer M. IgE mediated autoallergy against thyroid peroxidase--a novel pathomechanism of chronic spontaneous urticaria? PLoS One 2011; 6: e14794.
38. Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011; 128: 202-209. e5.
39. Gruber BL, Baeza ML, Marchese MJ, Agnello V, Kaplan AP. Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol 1988; 90: 213-7.
40. Hide M, Francis DM, Grattan CEH, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high affinity IgE receptor as a cause of histamine release in chronic urticaria. N Eng J Med 1993; 328: 1599-604.
41. Grattan CEH, Francis DM, Hide M, Greaves MW. Detection of circulating histamine releasing autoantibodies with functional properties of anti IgE in chronic urticaria. Clin Exp Allergy 1991; 21: 695-704.
42. Fiebiger E, Maurer D, Holub H, et al. Serum IgG autoantibodies directed against the alpha chain of FceRI: a selective marker and pathogenetic factor for a distinct subset of chronic urticaria patients? J Clin Invest 1995; 96: 2606-12.
43. Ferrer M, Kinet JP, Kaplan AP. Comparative studies of functional and binding assays for IgG anti-FceRIa (a-subunit). J Allergy Clin Immunol 1998; 101: 672-6.
44. Greaves M. Chronic urticaria. J Allergy Clin Immunol 2000; 105: 664-72.
45. Asero R, Tedeschi A, Lorini M, Salimbeni R, Zanoletti T, Miadonna A. Chronic urticaria: novel clinical and serological aspects. Clin Exp Allergy 2001; 31: 1105-10.
46. Fagiolo U, Kricek F, Ruf C, Peserico A, Amadori A, Cancian M. Effects of complement inactivation and IgG depletion on skin reactivity to autologous serum in chronic idiopathic urticaria. J Allergy Clin Immunol 2000; 106: 567-72.
47. Asero R, Tedeschi A, Riboldi P, Cugno M. Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum. J Allergy Clin Immunol 2006; 117: 1113-7.
48. Goldsack NR, Chambers RC, Dabbagh K, Laurent GJ. Thrombin. Int J Biochem Cell Biol 1998; 30: 641-9.
49. Schaeffer RC, Gong F, Bitrick MS, Smith TL. Thrombin and bradykinin initiate discrete endothelial solute permeability mechanisms. Am J Physiol 1993; 264: 1798-809.
50. Cirino G, Cicala C, Bucci MR, Sorrentino L, Maranganore JM, Stone SR. Thrombin functions as an inflammatory mediator through activation of its receptors. J Exp Med 1996; 183: 821-7.
51. Vliagoftis H. Thrombin induces mast cell adhesion tofibronectin: evidence for the involvement of protease-activated receptor-1. J Immunol 2002; 169: 4551-8.
52. Razin E, Marx G. Thrombin-induced degranulation of cultured bone marrow-derived mast cells. J Immunol 1984; 133: 3282-5.
53. Asero R, Tedeschi A, Coppola R, et al. Activation of the tissue pathway of blood coagulation in patients with chronic urticaria. J Allergy Clin Immunol 2007; 119: 705-10.
54. Cugno M, Marzano AV, Tedeschi A, Fanoni D, Venegoni L, Asero R. Expression of tissue factor by eosinophils in patients with chronic urticaria. Int Arch Allergy Immunol 2009; 148: 170-4.
55. Asero R, Tedeschi A, Riboldi P, Griffini S, Bonanni E, Cugno M. Severe chronic urticaria is associated with elevated plasma levels of D-dimer. Allergy 2008; 63: 176-80.
56. Moosbauer C, Morgenstern E, Cuvelier SL, et al. Eosinophils are a major intravascular location for tissue factor storage and exposure. Blood 2007; 109: 995-1002.
57. Wang F, Tang H, Xu J, Kang K. Activation of the blood coagulation cascade is involved in patients with chronic urticaria. J Allergy Clin Immunol 2009; 123: 972-3.
58. Fujii K, Usuki A, Kan-No Y, Ohgou N. Elevation of circulating thrombin-antithrombin III complex and fibrin degradation products in urticaria. A laboratory finding unrelated to intravascular coagulopathy. J Dermatol 2008; 35: 308-10.
59. Khalaf AT, Liu XM, Sheng WX, Tan JQ, Abdalla AN. Efficacy and safety of desloratadine combined with dipyridamole in the treatment of chronic urticaria. J Eur Acad Dermatol Venereol 2008; 22: 487-92.
60. Takeda T, Sakurai Y, Takahagi S, et al. Increase of coagulation potential in chronic spontaneous urticaria. Allergy 2011; 66: 428-33.
61. Monroe EW, Daly AF, Shalhoub RF. Appraisal of the validity of histamine-induced wheal and flare to predict the clinical efficacy of antihistamines. J Allergy Clin Immunol 1997; 99: S798-S806.
62. Cugno M, Zanichelli A, Foieni F, et al. C1-inhibitor deficiency and angioedema: Molecular mechanisms and clinical progress. Trends Mol Med 2009; 15: 69-78.
63. Cichon S, Martin L, Hennies HC, et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006; 79: 1098-104.
64. Cugno M, Castelli R, Cicardi M. Angioedema due to acquired C1-inhibitor deficiency: A bridging condition between autoimmunity and lymphoproliferation. Autoimmun Rev 2008; 8: 156-9.
65. Davis AE III. C1 inhibitor and hereditary angioneurotic edema. Annu Rev Immunol 1988; 6: 595-628.
66. Cugno M, Bergamaschini L, Uziel L, et al. Haemostasis contact system and fibrinolysis in hereditary angioedema (C1-inhibitor deficiency). J Clin Chem Clin Biochem 1988; 26: 423-7.
67. Cugno M, Cicardi M, Coppola R, Agostoni A. Activation of factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired C1-inhibitor deficiencies. Immunopharmacology 1996; 33: 361-4.
68. Cugno M, Nuijens J, Hack E, et al. Plasma levels of C1-inhibitor complexes and cleaved C1-inhibitor in patients with hereditary angioneurotic edema. J Clin Invest 1990; 85: 1215-20.
69. Cugno M, Cicardi M, Bottasso B, et al. Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood 1997; 89: 3213-8.
70. Cugno M, Zanichelli A, Bellatorre AG, et al. Plasma biomarkers of acute attacks in patients with angioedema due to C1-inhibitor deficiency. Allergy 2009; 64: 254-7.
71. Cugno M, Cicardi M, Agostoni A. Activation of the contact system and fibrinolysis in autoimmune acquired angioedema: A rationale for prophylactic use of tranexamic acid. J Allergy Clin Immunol 1994; 93: 870-6.
72. Cugno M, Hack CE, de Boer JP, et al. Generation of plasmin during acute attacks of hereditary angioedema. J Lab Clin Med 1993; 121: 38-43.
73. Schaeffer RC Jr, Gong F, Bitrick MS Jr, Smith TL: Thrombin and bradykinin initiate discrete endothelial solute permeability mechanisms. Am J Physiol 1993; 264: H1798.
74. Ehringer WD, Edwards MJ, Miller FN. Mechanisms of a-thrombin, histamine, and bradykinin induced endothelial permeability. J Cell Physiol 1996; 167: 562.
75. Donaldson VH. Blood coagulation and related plasma enzymes in inflammation. Ser Haemat 1970; 3: 39.
76. Marzano AV, Tedeschi A, Fanoni D, et al. Activation of blood coagulation in bullous pemphigoid: role of eosinophils, and local and systemic implications. Br J Dermatol 2009; 160: 266-72.
77. Marzano AV, Tedeschi A, Spinelli D, Fanoni D, Crosti C, Cugno M. Coagulation activation in autoimmune bullous diseases. Clin Exp Immunol 2009; 158: 31-6.
78. Marzano AV, Tedeschi A, Berti E, Fanoni D, Crosti C, Cugno M. Activation of coagulation in bullous pemphigoid and other eosinophil-related inflammatory skin diseases. Clin Exp Immunol 2011; 165: 44-50.
79. So AK, Varisco PA, Kemkes-Matthes B, et al. Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J Thromb Haemost 2003; 1: 2510-5.
80. Kume K, Yamasaki M, Tashiro M, et al. Activations of coagulation and fibrinolysis secondary to bowel inflammation in patients with ulcerative colitis. Intern Med 2007; 46: 1323-9.
81. Liaw PC, Esmon CT, Kahnamoui K, et al. Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood 2004; 104: 3958-64.
82. Teitel JM, Bauer KA, Lau HK, Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1? 2 fragment and thrombin-antithrombin complex. Blood 1982; 59: 1086-97.
83. Boneu B, Bes G, Pelzer H, Sie P, Boccalon H. D-Dimers, thrombin antithrombin III complexes and prothrombin fragments 1+2: diagnostic value in clinically suspected deep vein thrombosis. Thromb Haemost 1991; 65: 28-31.
84. van Deventer SJ, Büller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990; 76: 2520-6.
85. Takeda T, Sakurai Y, Takahagi S, et al. Increase of coagulation potential in chronic spontaneous urticaria. Allergy 2011; 66: 428-33.
86. Vaswani SK, Plack RH, Norman PS. Acute severe urticaria and angioedema leading to myocardial infarction. Ann Allergy Asthma Immunol 1996; 77: 101-4.
87. Pontillo D, Capezzuto A, Castellani R. Acute generalized urticaria leading to acute myocardial infarction. Angiology 2000; 51: 89-90.
88. Yaegashi T, Nakamura Y, Sakagami S, Saeki T, Omi W, Ikeda K. Acute myocardial infarction following food-dependent exerciseinduced anaphylaxis. Intern Med. 2011; 50: 451-4.
89. Connor S, Child N, Burdon-Jones D, Connor A. Cardiac arrest secondary to type 2 Kounis syndrome resulting from urticaria and angioedema. Emerg Med J 2010; 27: 568-9.
90. Meyer-De Schmid JJ, Neuman A. Treatment of chronic urticaria with heparin. Bull Soc Fr Dermatol Syphiligr 1952; 59: 286-7.
91. Chua SL, Gibbs S. Chronic urticaria responding to subcutaneous heparin sodium. Br J Dermatol 2005; 153: 216-7.
92. Parslew R, Pryce D, Ashworth J, Friedmann PS. Warfarin treatment of chronic idiopathic urticaria and angio-oedema. Clin Exp Allergy 2000; 30: 1161-5.
93. Mahesh PA, Pudupakkam VK, Holla AD, Dande T. Effect of warfarin on chronic idiopathic urticaria. Indian J Dermatol Venereol Leprol 2009; 75: 187-9.
94. Cicardi M, Bergamaschini L, Zingale LC, Gioffré D, Agostoni A. Idiopathic non-histaminergic angioedema. Am J Med 1999; 106: 650-4.
95. Tant D. Tranexamic acid in chronic urticaria. Br Med J 1979; 1: 266.
96. Laurberg G. Tranexamic acid (Cyklokapron) in chronic urticaria: a double-blind study. Acta Derm Venereol 1977; 57: 369-70.
97. Asero R, Tedeschi A, Cugno M. Heparin and tranexamic Acid therapy may be effective in treatment-resistant chronic urticaria with elevated d-dimer: a pilot study. Int Arch Allergy Immunol 2010; 152: 384-9.